European cardiologists to review Multaq; Roche plots sale of Boulder plant;

@FiercePharma: Surprise Provenge shortfall triggers Dendreon layoffs. Story | Follow @FiercePharma

> The European Society of Cardiology will review its atrial fibrillation treatment guidelines in light of a recently halted Multaq trial that raised safety questions about using the Sanofi drug in patients with permanent AF. Report

> An Abbott Laboratories plant in Temecula, CA, is the first business to be admitted to a foreign trade zone with boundaries recently redrawn to help area companies. Item

> Roche plans to sell its 256-employee manufacturing plant in Boulder, CO, to International Chemical Investors Group for use by the company's Corden Pharma group. Story

> Enzon Pharmaceuticals posted a larger quarterly loss as royalties from its hepatitis C drug Pegintron dropped. News

> Aspen Pharmacare reportedly won 29% of a 485 million rand ($70 million) tender to supply the South African government with tuberculosis drugs. Article

> The cost of Medicare Part D is dropping, with beneficiaries paying an average of $30 per month for a plan. Piece

Biotech News

@FierceBiotech: Be the first to meet the 2011 Fierce 15. News | Follow @FierceBiotech

@JohnCFierce: Texas Gov. Rick Perry gets a stem cell treatment, then lobbies for the procedure. Article | Follow @JohnCFierce

@MaureenFierce: 104-year-old 'super ager' can thank her lucky genes. Article | Follow @MaureenFierce

> Takeda, Amylin pull plug on obesity trial. News

> Questionable timing: House pushes biotech tax breaks. Article

> Dendreon releases death-eaters into biotech sector stocks. Report

And Finally... Japanese scientists make working mouse sperm from embryonic stem cells. More

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.